Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Boguniewicz

Showing results (61-70 of 160) with videos related to

Pageof 16
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2001
Decreased IL-15 may contribute to elevated IgE and acute inflammation in atopic dermatitisPeck Y Ong, Qutayba A Hamid, Jeffrey B Travers, et al.
Journal of the American Academy of Dermatology|July 16, 2005
Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitisM Shane Chapman, Lawrence A Schachner, Debra Breneman, et al.
Immunity|March 21, 2006
Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virusMichael D Howell, Richard L Gallo, Mark Boguniewicz, et al.
Allergy|July 17, 2023
Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibitionEric L Simpson, Emma Guttman-Yassky, Lawrence F Eichenfield, et al.
Journal of Drugs in Dermatology : JDD|August 3, 2007
A multiple-domain framework of clinical, economic, and patient-reported outcomes for evaluating benefits of intervention in atopic dermatitisMark Boguniewicz, William Abramovits, Amy Paller, et al.
The Journal of Allergy and Clinical Immunology|June 9, 2005
Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and ImmunologyLuz Fonacier, Jonathan Spergel, Ernest N Charlesworth, et al.
Journal of the American Academy of Dermatology|March 22, 2002
Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescentsLawrence F Eichenfield, Anne W Lucky, Mark Boguniewicz, et al.
The New England Journal of Medicine|October 11, 2002
Endogenous antimicrobial peptides and skin infections in atopic dermatitisPeck Y Ong, Takaaki Ohtake, Corinne Brandt, et al.
Advances in Therapy|October 29, 2024
Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 ComorbiditiesMark Boguniewicz, Lawrence D Sher, Amy S Paller, et al.
The Journal of Allergy and Clinical Immunology|December 5, 2006
Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virusByung Eui Kim, Donald Y M Leung, Joanne E Streib, et al.
Pageof 16

Showing results (61-70 of 160) with videos related to

Sort By:
Pageof 16
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2001
Decreased IL-15 may contribute to elevated IgE and acute inflammation in atopic dermatitisPeck Y Ong, Qutayba A Hamid, Jeffrey B Travers, et al.
Journal of the American Academy of Dermatology|July 16, 2005
Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitisM Shane Chapman, Lawrence A Schachner, Debra Breneman, et al.
Immunity|March 21, 2006
Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virusMichael D Howell, Richard L Gallo, Mark Boguniewicz, et al.
Allergy|July 17, 2023
Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibitionEric L Simpson, Emma Guttman-Yassky, Lawrence F Eichenfield, et al.
Journal of Drugs in Dermatology : JDD|August 3, 2007
A multiple-domain framework of clinical, economic, and patient-reported outcomes for evaluating benefits of intervention in atopic dermatitisMark Boguniewicz, William Abramovits, Amy Paller, et al.
The Journal of Allergy and Clinical Immunology|June 9, 2005
Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and ImmunologyLuz Fonacier, Jonathan Spergel, Ernest N Charlesworth, et al.
Journal of the American Academy of Dermatology|March 22, 2002
Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescentsLawrence F Eichenfield, Anne W Lucky, Mark Boguniewicz, et al.
The New England Journal of Medicine|October 11, 2002
Endogenous antimicrobial peptides and skin infections in atopic dermatitisPeck Y Ong, Takaaki Ohtake, Corinne Brandt, et al.
Advances in Therapy|October 29, 2024
Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 ComorbiditiesMark Boguniewicz, Lawrence D Sher, Amy S Paller, et al.
The Journal of Allergy and Clinical Immunology|December 5, 2006
Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virusByung Eui Kim, Donald Y M Leung, Joanne E Streib, et al.
Pageof 16